The company had posted a net profit of Rs 136.74 crore in the same period of the previous fiscal.
Net sales of the company declined to Rs 750.98 crore during the first quarter, compared to Rs 928.20 crore during the June quarter of 2014-15 fiscal, Ipca Laboratories said in a filing to the BSE.
"The income and profitability of the company was impacted in the first quarter due to USFDA import alert on three manufacturing units, lower anti-malarial institutional business and impact in the emerging markets due to currency fluctuations," it added.
The company is implementing comprehensive remedial measures at all its manufacturing sites to ensure regulatory compliances, it said.
Ipca shares were trading at Rs 680.30 apiece on the BSE, down 1.46 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)